基因修饰的靶向CD19并分泌IL-15的NK细胞用于治疗系统性红斑狼疮
研究将外周血来源NK细胞工程化改造为表达CAR.CD19/IL-15(XB-19.15)或单用CAR.CD19,体外及人源化小鼠模型显示XB-19.15细胞毒性更强、IL-15持续分泌、增殖增强,并可深度清除B细胞和浆细胞、降低hIgG和抗dsDNA抗体;1期试验中3例难治性SLE患者接受XB-19.15后疾病活动度改善、B细胞 repertoire 重置,未出现严重不良事件。
要点
- XB-19.15在体外对CD19+细胞显示更强细胞毒性、持续IL-15分泌和增强的增殖。
- 小鼠模型中XB-19.15呈剂量依赖性肿瘤消退并长期存续于多种淋巴器官。
- SLE异种移植模型中XB-19.15治疗组hIgG和抗dsDNA抗体水平下降。
核心结论
- XB-19.15可实现强效、持久的B细胞清除和SLE免疫重置,具有现货型(off-the-shelf)应用潜力和良好安全性。
- 临床前和早期临床数据支持进一步试验以优化给药方案并确认长期疗效。
研究设计与样本
- 研究为临床前体外与体内实验联合1期概念验证试验,体外使用外周血来源NK细胞工程化改造为CAR.CD19/IL-15(XB-19.15)或单用CAR.CD19。
- 体内模型包括Nalm6-luc异种移植、人源化CD34+小鼠和SLE外周血单个核细胞异种移植,评估疗效、持久性和安全性。
- 1期试验入组3例难治性SLE患者接受XB-19.15治疗。
主要发现
- 体外实验中XB-19.15显示更强的细胞毒性、持续的IL-15分泌和增强的增殖(Ki-67)。
- 小鼠模型中XB-19.15呈显著剂量依赖性Nalm-6肿瘤消退,并在人源化小鼠中实现B细胞清除且长期存续于多种淋巴器官。
- SLE异种移植模型中XB-19.15治疗组hIgG和抗dsDNA抗体总水平下降,骨髓和脾脏B细胞及浆细胞深度清除。
- 3例接受XB-19.15的难治性SLE患者疾病活动度改善、B细胞 repertoire 重置,未发生严重不良事件。
局限性
- 1期试验仅入组3例难治性SLE患者,属概念验证性研究。
- 原文结论指出需进一步试验以优化给药方案并确认长期疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Given the efficacy of B-cell depletion therapy in systemic lupus erythematosus (SLE) treatment and the capacity of engineered natural killer (NK) cells in B-cell elimination, we explored the potential of genetically modified NK cells to target CD19 for the treatment of SLE. METHODS: Peripheral blood-derived NK cells were engineered with CAR.CD19/interleukin (IL)-15 (XB-19.15) or CAR.CD19 alone. In vitro assays tested cytotoxicity, proliferation (Ki-67), and cytokine release (IL-15/interferon-gamma [IFN-γ]] against CD19+ cells (Raji, Nalm6, SLE B-cell). In vivo models included Nalm6-luc xenografts, humanised CD34+ mice, and SLE peripheral blood mononuclear cells xenografts to assess efficacy, persistence, and safety. A phase 1 trial enrolled 3 patients with refractory SLE receiving XB-19.15 as a proof-of-concept study. RESULTS: XB-19.15 showed superior cytotoxicity, sustained IL-15 secretion, and enhanced proliferation in vitro. In the mouse model, XB-19.15 showed significant dose-dependent tumour regression of Nalm-6 and B-cell depletion of humanised mice with long-term persistence in various lymphoid organs. The total levels of hIgG and anti-dsDNA antibodies were decreased in XB-19.15-treated groups with deep clearance of B-cell and plasma cells of bone marrow and spleen in the SLE xenograft model, indicating potential attenuation of SLE. Three patients received XB-19.15 achieved improvement in disease activity and reset of B-cell repertoires without severe adverse events. CONCLUSIONS: XB-19.15 enables potent, durable B-cell depletion and immune resetting in SLE with off-the-shelf utility and favourable safety. Preclinical and early clinical data support further trials to optimise dosing and confirm long-term efficacy.
引用
- Fu Y, Xu Z, Wu C, et al. Genetically modified CD19-targeting IL-15 secreting NK cells for the treatment of systemic lupus erythematosus. Ann Rheum Dis. 2025. PMID: 40858468. doi:10.1016/j.ard.2025.07.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。